SB203580, PD98059 or SP6000125 treatment significantly decreased serum creatinine, blood urea nitrogen and serum NGAL (Fig. 5a–c) levels, suggesting that inhibiting MAPK signalling protected renal function in this nephrolithiasis model. Here, LCN2 is linked to nephrolithiasis.